Pancreatic cancer is usually found too late. A new strategy called interception, backed by a drug approved only weeks ago, is trying to change that. This is the story of how researchers want to catch it early and treat it before it spreads.
Pancreatic cancer interception means finding abnormal tissue early and treating it before it turns into a spreading tumor. The idea is already being tested in breast and skin cancers. Pancreatic cancer, one of the hardest tumors to treat, was long considered out of reach. Now researchers think that may be changing.
The drug that shifted the mood
The catalyst is daraxonrasib, sold as Rasonque. It is approved for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or can’t take multiagent therapy. In the Phase 3 trial behind the approval, patients on the drug lived a median of 13.2 months, against 6.7 months on chemotherapy. It is the first approved RAS-targeting therapy that works broadly in this disease, and RAS mutations were long considered “undruggable.”
It isn’t a cure. But at the September AACR pancreatic cancer conference in San Diego, the first since the approval, interception was one of the main topics.
Why early is everything
The numbers explain the excitement. According to Diane Simeone, director of the Moores Cancer Center at UC San Diego Health, five-year survival can top 80% when pancreatic tumors are caught early. Yet overall five-year survival sits at 13.7%. The reason is timing. Symptoms are vague, people delay seeing a doctor, and more than half of cases are diagnosed after the cancer has already reached other organs. Simeone says that figure has barely moved in the 30 years since she opened her lab.
Her bet is that early detection plus interception “is going to be the breakthrough strategy that really changes survival.” She told the conference it could lift five-year survival to 50%. That is a goal, not a result.
The study trying to prove it
Her team’s PRECEDE study aims to enroll 20,000 people at high risk: those with a family history, certain abnormal growths on the pancreas, or a risky genetic profile. A little over 12,000 are in so far, and more than 50 have been diagnosed with pancreatic cancer, many at the earliest stages.
The samples will be used to test experimental blood tests for early detection. The team also plans to see whether AI can spot abnormalities on scans before the human eye can. Another possible step is giving drugs like daraxonrasib right after surgery to remove precancerous growths or early tumors. For now, the drug is approved only for advanced disease, though it is also being tested on its own after surgery to see if it prevents recurrence.
Early evidence, and a long road
The support so far comes from animals. Ben Stanger’s lab at the University of Pennsylvania worked with mice carrying cancer-driving Kras mutations. When tiny precancerous growths appeared in the pancreas, the team gave a drug that disables KRAS and related proteins, as daraxonrasib does. The mice survived longer. Stanger calls it “super exciting,” but says working out how to use this in people could take years.
What to make of it
Interception depends on three things working at once: finding the people at risk, spotting trouble early, and treating it safely. The third is the hardest. A drug approved for dying patients can tolerate side effects that healthy-looking people at risk probably won’t. Treating people who may never develop cancer raises the safety bar considerably.
Still, the approach shifts the fight from a late-stage battle to an earlier one. RAS proteins are mutated in about 90% of pancreatic cancers, so a single drug class could apply to many patients. The next few years of PRECEDE data will show whether early detection and interception actually save lives.